Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTIOS: Ofatumumab in RMS Patients Transitioning From Fumarates or Fingolimod
NCT04353492Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Jul 2020; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04353492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353492.